Baxter International Inc. (NYSE: BAX), is an American health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. The company had 2009 sales of $12.6 billion, across three manufacturing divisions: BioScience (producing recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine; and vaccines); Medication Delivery (producing intravenous solutions and other products used in the delivery of fluids and drugs to patients, as well as inhalation anesthetics and contract manufacturing services); and Renal (providing products to treat end-stage renal disease, or irreversible kidney failure, including solutions and other products for peritoneal dialysis and hemodialysis).
Some of this data may be out of date
State influence data from the National Institute on Money in State Politics changed in format and availability during the 2013-2014 election cycle. While we work to integrate their new style of data release, state-level campaign finance data for the 2014 cycle and beyond will be unavailable. We apologize for the inconvenience, but heartily recommend trying out their snazzy new site at FollowTheMoney.org!
Campaign Finance$1,540,954 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
state-level data is not available in bulk for 2014. for current state data, browse http://followthemoney.org/
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Baxter International
Names of Lobbyists
Firm Hired Amount Baxter Healthcare $39,891,209
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Fed Budget & Appropriations,
- Copyright, Patent & Trademark,
- Disaster & Emergency Planning,
- Medical Research & Clin Labs
Most Frequently Disclosed Bills
Bill No. Title H.R.1765 (Unknown) H.R.3200 America's Affordable Health Choices Act of 2009 S.701 Medicare Patient IVIG Access Act of 2009 H.R.1845 Medicare IVIG Access Act H.R.4213 Tax Extenders Act of 2009 S.960 Medicare IVIG Access Act H.R.1260 Patent Reform Act of 2009 S.515 Patent Reform Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009
RegulationsMentioned in 100 dockets; Submitted to 5 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Baxter International" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Baxter International
- Toggle 1 FDA Electronic Distribution of Prescribing Information for Prescription Drug Products; Public Hearing 2007
- Toggle 1 FDA Draft Guidance for Industry on Current Good Manufacturing Practice — Interim Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act; Availability 2014
- Toggle 1 FDA Draft Guidance for Industry on Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products--Content and Format; Availability 2014
- Toggle 1 SEC Comments on Proposed Rule: Mandated Electronic Filing for Form ID 2004
- Toggle 1 FDA Request That FDA Confirm the Agency Will Stay Approval of Abbreviated New Drug Application No. 90-363, for 30 Months Beginning on June 23, 2009 - CLOSED 2011
Mentions in Document Text
View all mentions data for Baxter International
- Toggle 6 FDA Request That FDA Confirm the Agency Will Stay Approval of Abbreviated New Drug Application No. 90-363, for 30 Months Beginning on June 23, 2009 - CLOSED 2011
- Toggle 3 FDA Public Disclosure Materials for Emergency Research Studies Conducted under 21 CFR 50.24 1995
- Toggle 3 EPA NACEPT FY 2013 2013
- Toggle 3 EPA National Advisory Council for Environmental Policy and Technology (NACEPT) 2012 2013
- Toggle 2 FDA Permit the filing of an Abbreviated New drug application (ANDA) for a Piperacillin and Tazobactam for Injection 2011
- Toggle 2 EPA Preliminary 2006 Effluent Guidelines Program Plan 2004
- Toggle 2 FDA Improving Patient Safety by Enhancing the Container Labeling for Parenteral Infusion Drug Products; Public Meeting 2006
- Toggle 2 EPA Effluent Guidelines Program Plan for 2004/2005. 2003
- Toggle 2 SEC Comments on Study on Extraterritorial Private Rights of Action 2010
- Toggle 2 FDA Requests That the FDA Issue a Determination That the new Strengths of 200 mg/vial and 300 mg/vial of Ceftaroline Fosamil for Injection are Suitable for Submission as an ANDA. 2014
Federal Spending1 contract
Federal grants, contracts and loans are reported by federal agencies using the FPDS and FAADS systems. The data is made available to the public at USASpending.gov. Please note that the completeness and quality of the data varies greatly by agency.
Only grants, contracts and loans with amounts over $1 million are shown.
Because company names are not reported in a standardized manner, we cannot reliably determine the company receiving the contract or award. The results shown here are based on a search for the company name. Individual records may be missed or erroneously included because of name variations. For more information, please see our federal spending methodology page.
Note: Company names in federal spending data are not standardized. The table below is included only as a sample of what is available in the data and has not been reviewed for accuracy or completeness. To investigate the data further, use the links at the bottom of the table.
|Baxter International Inc||2000||Centers For Disease Control||$1,850,000|
Advisory Committees1 person on 1 committee
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Baxter International" that sat on federal advisory committees.
- Toggle Department of Commerce 1 person on 1 committee